Claims for Patent: 8,679,488

Summary for Patent: 8,679,488

Title:	Targeting of bone marrow neovasculature
Abstract:	Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).
Inventor(s):	Kaspar; Manuela (Brugg, CH), Schliemann; Christoph (Munster, DE), Neri; Dario (Buchs, CH)
Assignee:	Philogen S.p.A. (Siena, IT)
Application Number:	13/386,451
Patent Claims:	1. A method of treating acute myeloid leukemia comprising administering a therapeutically effective amount of an antibody that binds an antigen of the bone marrow neovasculature in acute myeloid leukemia patients to an individual in need thereof, wherein the antigen is the A1 domain of tenascin-C large isoform and the antibody competes for binding to tenascin-C with an antibody comprising the 4A1-F16 VH domain of SEQ ID NO:2 and the 4A1-F16 VL domain of SEQ ID NO:4. 2. A method according to claim 1, wherein the antibody is conjugated to a bioactive molecule selected from the group consisting of a cytokine, cytotoxic agent, photosensitizer, and a therapeutic radioisotope. 3. A method according to claim 2, wherein the antibody is conjugated to the bioactive molecule via a cleavable linker. 4. A method according to claim 1, or claim 2, wherein the method comprises administering the antibody and an anti-cancer compound to an individual in need thereof. 5. A method according to claim 1, wherein the antibody comprises an antigen binding site comprising a VH domain and a VL domain, the VH domain comprising a VH CDR1 of SEQ ID NO:5, a VH CDR2 of SEQ ID NO:6 and a VH CDR3 of SEQ ID NO:7, and the VL domain comprising a VL CDR1 of SEQ ID NO:8, a VL CDR2 of SEQ ID NO:9 and a VL CDR3 of SEQ ID NO:10. 6. A method according to claim 1, wherein the antibody comprises an antigen binding site comprising a VH domain and a VL domain, wherein the VH domain is the 4A1-F16 VH domain of SEQ ID NO:2 and the VL domain is the 4A1-F16 VL domain of SEQ ID NO:4. 7. A method according to claim 1, wherein the antibody is a small immunoprotein (SIP), scFv, or whole IgG molecule, said antibody binding the A1 domain of tenascin C large isoform. 8. The method as claimed in claim 4, wherein said bioactive agent is a IL-2 and said anticancer agent is selected from the group consisting of anthracyclines, cytarabine, vincristine, L-asparaginase, cyclophosphamide, methotrexate, 6-mercaptopurine, chlorambucil, cyclophosphamide, a corticosteroid, prednisone, prednisolone, imatinib, cladribine, pentostatin, rituximab, and doxorubicin. 9. The method as claimed in claim 8, wherein said anticancer agent is cytarabine.

Details for Patent 8,679,488

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2029-08-05
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2029-08-05
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2029-08-05
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2029-08-05